RxDoctor Payments Data

Jimmy Riggins, MD

Ophthalmology · Fayetteville, NCNPI 1285686865

Payments from drug & device makers

$2,663in general payments, 2019–2025

Across 74 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$892
  • Alcon$730
  • Biotissue Holdings Inc.$319
  • Bausch & Lomb Americas Inc.$232
  • Ocular Therapeutix, Inc.$174
  • Dompe US, Inc.$125
  • plus $191 from 5 others

What the payments were for

  • Food & beverage$2,64599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,663 in reported general payments places this provider in the 60th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$471,870
Medicare patients
683
Services billed
6,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost141$74,303
RestasisCyclosporine39$40,291
RocklatanNetarsudil Mesylat/Latanoprost49$25,597
VyzultaLatanoprostene Bunod41$22,314
Prednisolone Acetate580$16,409
SimbrinzaBrinzolamide/Brimonidine Tart63$13,326
MoxifloxacinMoxifloxacin Hcl414$10,819
Ketorolac Tromethamine467$9,029
Alphagan PBrimonidine Tartrate22$6,656
CombiganBrimonidine Tartrate/Timolol22$6,085
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat332$5,655
ValacyclovirValacyclovir Hcl112$5,543
Latanoprost405$5,526
Dorzolamide-TimololDorzolamide/Timolol/Pf39$5,406
Travoprost31$4,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$892$127,335224 claims
Bausch & Lomb Americas Inc.Vyzulta$232$22,31441 claims
AlconSimbrinza$730$13,32663 claims
Akorn, Inc.Betimol$22$2,65712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →